2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/2iy5wruuedsh6.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/00yc7rcvua6a7.js","/_next/static/immutable/chunks/37ktb71aq3480.js","/_next/static/immutable/chunks/2d50b-7eu4558.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/2d6noqpp6ehas.js","/_next/static/immutable/chunks/1sx186c93bpzg.js","/_next/static/immutable/chunks/3dc-1n866s65i.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2w1bvggzb0ga8.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T7e2,In real-world chronic obstructive pulmonary disease (COPD) care, poor adherence often leads to treatment discontinuations. Discontinuing inhaled corticosteroids (ICS) can trigger withdrawal effects transiently increasing exacerbation risk; but evidence for long-acting muscarinic antagonists (LAMA) withdrawal remains limited. We performed a post hoc analysis of the 52-week, double-blind, Effect of Indacaterol Glycopyrronium versus Fluticasone Salmeterol on COPD Exacerbations trial that compared long-acting beta-2 agonist (LABA)+LAMA with LABA+ICS in 3362 patients with moderate-to-severe COPD and exacerbation history. Potential withdrawal effects after discontinuing LAMA or ICS were suggested by monthly exacerbation incidence plots during the first quarter of follow-up. Participants were stratified by their baseline use of these therapies, and outcomes were compared between the first and subsequent quarters among those who continued versus discontinued each treatment. Multivariable mixed-effects models assessed differences in exacerbation rates, with temporal variation in treatment effects interpreted as indicative of withdrawal effects. Discontinuing LAMA was associated with a marked, transient increase in moderate-to-severe exacerbations during the first versus subsequent quarters (p=0.001; rate ratio up to 2.2 (95% CI 1.2 to 4.1) in the subgroup least influenced by concomitant ICS use). This observation was not confirmed for severe exacerbations, likely due to low event count. In contrast, discontinuing ICS was associated with a significant early rise in severe exacerbations (p=0.023), though the difference for moderate-to-severe events did not reach statistical significance. Importantly, ICS withdrawal effects appeared consistent regardless of baseline blood eosinophil count. Our findings suggest potent LAMA and ICS treatment withdrawal effects on exacerbations, highlighting the importance of treatment adherence and accounting for withdrawal effects in clinical trials. NCT01782326.31:Tb94, Background In real-world chronic obstructive pulmonary disease (COPD) care, poor adherence often leads to treatment discontinuations. Discontinuing inhaled corticosteroids (ICS) can trigger withdrawal effects transiently increasing exacerbation risk; but evidence for long-acting muscarinic antagonists (LAMA) withdrawal remains limited. Methods We performed a post hoc analysis of the 52-week, double-blind, Effect of Indacaterol Glycopyrronium versus Fluticasone Salmeterol on COPD Exacerbations trial that compared long-acting beta-2 agonist (LABA)+LAMA with LABA+ICS in 3362 patients with moderate-to-severe COPD and exacerbation history. Potential withdrawal effects after discontinuing LAMA or ICS were suggested by monthly exacerbation incidence plots during the first quarter of follow-up. Participants were stratified by their baseline use of these therapies, and outcomes were compared between the first and subsequent quarters among those who continued versus discontinued each treatment. Multivariable mixed-effects models assessed differences in exacerbation rates, with temporal variation in treatment effects interpreted as indicative of withdrawal effects. Results Discontinuing LAMA was associated with a marked, transient increase in moderate-to-severe exacerbations during the first versus subsequent quarters (p=0.001; rate ratio up to 2.2 (95% CI 1.2 to 4.1) in the subgroup least influenced by concomitant ICS use). This observation was not confirmed for severe exacerbations, likely due to low event count. In contrast, discontinuing ICS was associated with a significant early rise in severe exacerbations (p=0.023), though the difference for moderate-to-severe events did not reach statistical significance. Importantly, ICS withdrawal effects appeared consistent regardless of baseline blood eosinophil count. Conclusion Our findings suggest potent LAMA and ICS treatment withdrawal effects on exacerbations, highlighting the importance of treatment adherence and accounting for withdrawal effects in clinical trials. Trial registration number NCT01782326 . 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"indacaterol: generic Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on indacaterol (generic). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/generic/indacaterol\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Generics\",\"item\":\"https://www.reachrx.ai/hub/tag/generic\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"indacaterol\",\"item\":\"https://www.reachrx.ai/hub/tag/generic/indacaterol\"}]}}"}}]],["$","$L2f",null,{"title":"indacaterol: Research & Clinical Takeaways","description":"Explore research on indacaterol (generic) — efficacy, safety, and comparative data.","papers":[{"doi":"10.1136/thorax-2025-223282","pmid":"41402044","title":"Disproportionate increase in COPD exacerbation risk for 3 months after discontinuing LAMA or ICS: insights from the FLAME trial","journal_title":"Thorax","journal_issn":"0040-6376","published_at":"2025-12-17T00:00:00.000Z","url":"https://doi.org/10.1136/thorax-2025-223282","source_score":29,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2025-12-20","doi":"10.1136/thorax-2025-223282","days":"30","issn":"0040-6376","rank":"1","field":"Clinical Medicine","score":"29","category":"Respiratory System","categories":["Respiratory System"],"_categories":["Respiratory System"]},"pubmed":{"doi":"10.1136/thorax-2025-223282","title":"Disproportionate increase in COPD exacerbation risk for 3 months after discontinuing LAMA or ICS: insights from the FLAME trial.","journal":"Thorax","methods":"","results":"Discontinuing LAMA was associated with a marked, transient increase in moderate-to-severe exacerbations during the first versus subsequent quarters (p=0.001; rate ratio up to 2.2 (95% CI 1.2 to 4.1) in the subgroup least influenced by concomitant ICS use). This observation was not confirmed for severe exacerbations, likely due to low event count. In contrast, discontinuing ICS was associated with a significant early rise in severe exacerbations (p=0.023), though the difference for moderate-to-severe events did not reach statistical significance. Importantly, ICS withdrawal effects appeared consistent regardless of baseline blood eosinophil count.","abstract":"$30","keywords":["COPD Exacerbations","COPD Pharmacology"],"pubmed_id":"41402044","conclusions":"Our findings suggest potent LAMA and ICS treatment withdrawal effects on exacerbations, highlighting the importance of treatment adherence and accounting for withdrawal effects in clinical trials.","publication_date":"2025-12-17T00:00:00"},"crossref":{"DOI":"10.1136/thorax-2025-223282","URL":"https://doi.org/10.1136/thorax-2025-223282","ISSN":["0040-6376","1468-3296"],"link":[{"URL":"https://syndication.highwire.org/content/doi/10.1136/thorax-2025-223282","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"thorax-2025-223282","type":"journal-article","issue":null,"score":1,"title":["Disproportionate increase in COPD exacerbation risk for 3 months after discontinuing LAMA or ICS: insights from the FLAME trial"],"author":[{"given":"Alexander G","family":"Mathioudakis","sequence":"first","affiliation":[{"name":"Division of Immunology, Immunity to Infection and Respiratory Medicine, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK"},{"name":"North West Lung Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, England, UK"}]},{"given":"Sebastian","family":"Bate","sequence":"additional","affiliation":[{"name":"Research and Innovation, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK"},{"name":"Centre for Biostatistics, Division of Population Health, Health Services Research and Primary Care, Facutly of Biology, Medicine and Health, The University of Manchester, Manchester, UK"}]},{"given":"Victoria","family":"Chatzimavridou-Grigoriadou","sequence":"additional","affiliation":[{"name":"Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK"}]},{"given":"Pradeesh","family":"Sivapalan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Respiratory Medicine, Copenhagen University Hospital, Herlev and Gentofte, Herlev, Denmark"},{"name":"Department of Clinical Medicine, University of Copenhagen, Copenhagen, Capital Region of Denmark, Denmark"}]},{"given":"Jens-Ulrik Stæhr","family":"Jensen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Respiratory Medicine, Copenhagen University Hospital, Herlev and Gentofte, Herlev, Denmark"},{"name":"Department of Clinical Medicine, University of Copenhagen, Copenhagen, Capital Region of Denmark, Denmark"}]},{"given":"Nawar Diar","family":"Bakerly","sequence":"additional","affiliation":[{"name":"Respiratory Medicine, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, UK"}]},{"given":"Jørgen","family":"Vestbo","sequence":"additional","affiliation":[{"name":"Division of Immunology, Immunity to Infection and Respiratory Medicine, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK"},{"name":"Department of Medicine, Section of Respiratory Medicine, Copenhagen University Hospital, Herlev and Gentofte, Herlev, Denmark"}]},{"given":"Dave","family":"Singh","sequence":"additional","affiliation":[{"name":"Division of Immunology, Immunity to Infection and Respiratory Medicine, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK"},{"name":"North West Lung Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, England, UK"},{"name":"Medicines Evaluation Unit an IQVIA business, Wythenshawe, UK"}]}],"funder":[{"id":[{"id":"10.13039/501100000659","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/501100000659","name":"Research Trainees Coordinating Centre","award":["CL-2021-06-007"],"award-info":[{"award-number":["CL-2021-06-007"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100014653","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100014653","name":"Manchester Biomedical Research Centre","award":["NIHR203308"],"award-info":[{"award-number":["NIHR203308"]}],"doi-asserted-by":"publisher"},{"name":"Pickering Fellowship, North West Lung Centre Charity","award":["No award/grant number"],"award-info":[{"award-number":["No award/grant number"]}]}],"issued":{"date-parts":[[2025,12,15]]},"member":"239","prefix":"10.1136","source":"Crossref","volume":null,"created":{"date-time":"2025-12-16T07:25:21Z","timestamp":1765869921000,"date-parts":[[2025,12,16]]},"indexed":{"date-time":"2025-12-16T07:30:15Z","timestamp":1765870215677,"date-parts":[[2025,12,16]]},"subject":[],"abstract":"$31","accepted":{"date-parts":[[2025,11,11]]},"language":"en","relation":{},"resource":{"primary":{"URL":"https://thorax.bmj.com/lookup/doi/10.1136/thorax-2025-223282"}},"subtitle":[],"deposited":{"date-time":"2025-12-16T07:25:28Z","timestamp":1765869928000,"date-parts":[[2025,12,16]]},"issn-type":[{"type":"print","value":"0040-6376"},{"type":"electronic","value":"1468-3296"}],"published":{"date-parts":[[2025,12,15]]},"publisher":"BMJ","reference":[{"DOI":"10.1016/S0140-6736(24)00367-2","key":"2025121523251543000_thorax-2025-223282v1.1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Collaborators GBDCoD . Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 2024;2100–32. doi:10.1016/S0140-6736(24)00367-2","article-title":null,"journal-title":null,"doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(24)00757-8","key":"2025121523251543000_thorax-2025-223282v1.2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Diseases GBD, Injuries C . Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 2024;2133–61. doi:10.1016/S0140-6736(24)00757-8","article-title":null,"journal-title":null,"doi-asserted-by":"crossref"},{"DOI":"10.1183/13993003.00239-2023","key":"2025121523251543000_thorax-2025-223282v1.3","year":"2023","issue":null,"author":"Agustí","volume":"61","first-page":null,"unstructured":null,"article-title":"Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary","journal-title":"Eur Respir J","doi-asserted-by":"crossref"},{"DOI":"10.1183/20734735.0267-2022","key":"2025121523251543000_thorax-2025-223282v1.4","year":"2023","issue":null,"author":"Stolz","volume":"19","first-page":null,"unstructured":null,"article-title":"Current and future developments in the pharmacology of asthma and COPD: ERS seminar, Naples 2022","journal-title":"Breathe (Sheff)","doi-asserted-by":"crossref"},{"DOI":"10.1183/13993003.01655-2017","key":"2025121523251543000_thorax-2025-223282v1.5","year":"2017","issue":null,"author":"Agustí","volume":"50","first-page":null,"unstructured":null,"article-title":"Precision medicine in airway diseases: moving to clinical practice","journal-title":"Eur Respir J","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ccm.2020.05.005","key":"2025121523251543000_thorax-2025-223282v1.6","year":"2020","issue":null,"author":"Mathioudakis","volume":"41","first-page":"463","unstructured":null,"article-title":"Long-Acting Bronchodilators for Chronic Obstructive Pulmonary Disease: Which One(S), How, and When?","journal-title":"Clin Chest Med","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.chest.2024.06.3790","key":"2025121523251543000_thorax-2025-223282v1.7","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1183/13993003.02119-2019","key":"2025121523251543000_thorax-2025-223282v1.8","year":"2020","issue":null,"author":"Mathioudakis","volume":"55","first-page":"32108044","unstructured":null,"article-title":"Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD","journal-title":"Eur Respir J","doi-asserted-by":"crossref"},{"DOI":"10.1183/20734735.0260-2022","key":"2025121523251543000_thorax-2025-223282v1.9","year":"2023","issue":null,"author":"Soumagne","volume":"19","first-page":null,"unstructured":null,"article-title":"Impact of triple therapy on mortality in COPD","journal-title":"Breathe (Sheff)","doi-asserted-by":"crossref"},{"DOI":"10.1016/S2213-2600(18)30006-7","key":"2025121523251543000_thorax-2025-223282v1.10","year":"2018","issue":null,"author":"Bafadhel","volume":"6","first-page":"117","unstructured":null,"article-title":"Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials","journal-title":"Lancet Respir Med","doi-asserted-by":"crossref"},{"DOI":"10.1183/09031936.00098307","key":"2025121523251543000_thorax-2025-223282v1.11","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1752-699X.2010.00198.x","key":"2025121523251543000_thorax-2025-223282v1.12","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1183/09059180.05.00009604","key":"2025121523251543000_thorax-2025-223282v1.13","year":"2005","issue":null,"author":"Rand","volume":"14","first-page":"97","unstructured":null,"article-title":"Patient adherence with COPD therapy","journal-title":"Eur Respir Rev","doi-asserted-by":"crossref"},{"DOI":"10.3390/ijerph191811573","key":"2025121523251543000_thorax-2025-223282v1.14","year":"2022","issue":null,"author":"Homętowska","volume":"19","first-page":null,"unstructured":null,"article-title":"Treatment Adherence in Patients with Obstructive Pulmonary Diseases","journal-title":"Int J Environ Res Public Health","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.pec.2024.108465","key":"2025121523251543000_thorax-2025-223282v1.15","year":"2025","issue":null,"author":"Liu","volume":"130","first-page":"108465","unstructured":null,"article-title":"Path analysis of illness perception, medication beliefs, family support on inhaler adherence in elderly COPD patients: Based on triadic reciprocal determinism","journal-title":"Patient Educ Couns","doi-asserted-by":"crossref"},{"DOI":"10.2147/COPD.S460903","key":"2025121523251543000_thorax-2025-223282v1.16","year":"2024","issue":null,"author":"Vogelmeier","volume":"19","first-page":"1835","unstructured":null,"article-title":"Evaluation of Adherence and Persistence to Triple Therapy in Patients with COPD: A German Claims Data Study","journal-title":"Int J Chron Obstruct Pulmon Dis","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa1516385","key":"2025121523251543000_thorax-2025-223282v1.17","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1177/17534666221107314","key":"2025121523251543000_thorax-2025-223282v1.18","year":"2022","issue":null,"author":"Singh","volume":"16","first-page":"17534666221107314","unstructured":null,"article-title":"Predictive modeling of COPD exacerbation rates using baseline risk factors","journal-title":"Ther Adv Respir Dis","doi-asserted-by":"crossref"},{"DOI":"10.1136/thorax-2024-222547","key":"2025121523251543000_thorax-2025-223282v1.19","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1183/13993003.00351-2020","key":"2025121523251543000_thorax-2025-223282v1.20","year":"2020","issue":null,"author":"Chalmers","volume":"55","first-page":"32366483","unstructured":null,"article-title":"Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline","journal-title":"Eur Respir J","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa1407154","key":"2025121523251543000_thorax-2025-223282v1.21","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S2213-2600(16)00100-4","key":"2025121523251543000_thorax-2025-223282v1.22","year":"2016","issue":null,"author":"Watz","volume":"4","first-page":"390","unstructured":null,"article-title":"Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial","journal-title":"Lancet Respir Med","doi-asserted-by":"crossref"},{"DOI":"10.1164/rccm.201803-0405OC","key":"2025121523251543000_thorax-2025-223282v1.23","year":"2018","issue":null,"author":"Chapman","volume":"198","first-page":"329","unstructured":null,"article-title":"Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial","journal-title":"Am J Respir Crit Care Med","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa1715275","key":"2025121523251543000_thorax-2025-223282v1.24","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1901963","key":"2025121523251543000_thorax-2025-223282v1.25","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"}],"short-title":[],"update-policy":"https://doi.org/10.1136/crossmarkpolicy","alternative-id":["10.1136/thorax-2025-223282"],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Thorax"],"reference-count":25,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,12,15]]},"references-count":25,"clinical-trial-number":[{"registry":"10.18810/clinical-trials-gov","clinical-trial-number":"nct01782326"}],"short-container-title":["Thorax"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1136/thorax-2025-223282","is_oa":false,"title":"Disproportionate increase in COPD exacerbation risk for 3 months after discontinuing LAMA or ICS: insights from the FLAME trial","updated":"2025-12-17T23:50:37+00:00","published_date":"2025-12-15","best_oa_location":null}},"created_at":"2026-01-17T09:03:27.421Z","updated_at":"2026-01-19T09:31:36.873Z","tags":[{"paper_doi":"10.1136/thorax-2025-223282","tag_type":"category","value":"Respiratory System","value_numeric":null},{"paper_doi":"10.1136/thorax-2025-223282","tag_type":"condition","value":"Chronic Obstructive Pulmonary Disease","value_numeric":null},{"paper_doi":"10.1136/thorax-2025-223282","tag_type":"generic","value":"fluticasone","value_numeric":null},{"paper_doi":"10.1136/thorax-2025-223282","tag_type":"generic","value":"glycopyrronium","value_numeric":null},{"paper_doi":"10.1136/thorax-2025-223282","tag_type":"generic","value":"indacaterol","value_numeric":null},{"paper_doi":"10.1136/thorax-2025-223282","tag_type":"generic","value":"salmeterol","value_numeric":null},{"paper_doi":"10.1136/thorax-2025-223282","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1136/thorax-2025-223282","tag_type":"modality","value":"Inhaled Corticosteroid","value_numeric":null},{"paper_doi":"10.1136/thorax-2025-223282","tag_type":"modality","value":"LAMA","value_numeric":null},{"paper_doi":"10.1136/thorax-2025-223282","tag_type":"sample_size","value":"n=3362","value_numeric":3362},{"paper_doi":"10.1136/thorax-2025-223282","tag_type":"study_design","value":"Post Hoc Analysis","value_numeric":null},{"paper_doi":"10.1136/thorax-2025-223282","tag_type":"warning","value":"Design is a post hoc analysis of a randomized trial; withdrawal effects are inferred rather than randomized.","value_numeric":null},{"paper_doi":"10.1136/thorax-2025-223282","tag_type":"warning","value":"Severe exacerbation findings, particularly for LAMA discontinuation, were limited by low event counts.","value_numeric":null},{"paper_doi":"10.1136/thorax-2025-223282","tag_type":"warning","value":"The rate ratio (up to 2.2) was reported for a subgroup least influenced by concomitant ICS; applicability to all patients may differ.","value_numeric":null}],"summaries":{"what_studied":"Post hoc analysis of the 52-week FLAME randomized trial (n=3362) in moderate-to-severe COPD with prior exacerbations assessed whether stopping LAMA or ICS increased exacerbations during the first quarter (first 3 months) versus later quarters, stratified by baseline use.","key_result":"Stopping LAMA increased moderate-to-severe exacerbations in the first vs subsequent quarters (p=0.001; rate ratio up to 2.2, 95% CI 1.2–4.1 in the subgroup least influenced by concomitant ICS), without a confirmed signal for severe events. Stopping ICS produced an early rise in severe exacerbations (p=0.023), with no statistically significant difference for moderate-to-severe events; this effect did not vary by baseline blood eosinophil count.","limitations":"Post hoc design with withdrawal effects inferred from temporal variation rather than randomized discontinuation. Severe exacerbation analyses were underpowered, and the LAMA signal was most evident in a subgroup least affected by concomitant ICS.","practice_takeaway":"Expect a transient rise in COPD exacerbations in the first 3 months after stopping LAMA or ICS; reinforce adherence and monitor closely soon after withdrawal. The early ICS withdrawal risk for severe events appears independent of baseline blood eosinophil count."}}],"initialOffset":1,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"generic","value":"indacaterol"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Generics","href":"/hub/tag/generic"},{"name":"indacaterol"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"generic","hub_tag_value":"indacaterol"}}}]]

Papers